MeiraGTx Holdings plc - Ordinary Shares (MGTX): Price and Financial Metrics

MeiraGTx Holdings plc - Ordinary Shares (MGTX): $6.58

0.28 (+4.44%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MGTX Price/Volume Stats

Current price $6.58 52-week high $11.57
Prev. close $6.30 52-week low $4.77
Day low $6.13 Volume 128,400
Day high $6.70 Avg. volume 151,281
50-day MA $5.80 Dividend yield N/A
200-day MA $7.10 Market Cap 391.51M

MGTX Stock Price Chart Interactive Chart >


MeiraGTx Holdings plc - Ordinary Shares (MGTX) Company Bio


MeiraGTx Limited develops gene therapies for acquired and inherited disorders. It offers products for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS); ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD); and xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. The company was founded in 2015 and is based in London, United Kingdom.


MGTX Latest News Stream


Event/Time News Detail
Loading, please wait...

MGTX Latest Social Stream


Loading social stream, please wait...

View Full MGTX Social Stream

Latest MGTX News From Around the Web

Below are the latest news stories about MEIRAGTX HOLDINGS PLC that investors may wish to consider to help them evaluate MGTX as an investment opportunity.

Wall Street Analysts Predict a 314.29% Upside in MeiraGTx Holdings PLC (MGTX): Here's What You Should Know

The consensus price target hints at a 314.3% upside potential for MeiraGTx Holdings PLC (MGTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | May 17, 2023

MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting

Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell TherapyLONDON and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit nine poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting, which is being held from May 16-20, 2023, in Los Angeles, CA. “Our presentation

Yahoo | May 16, 2023

MeiraGTx Reports First Quarter 2023 Financial and Operational Results

Raised approximately $60 million in a private placement in May 2023 with investors consisting of several of the Company’s top shareholders On track for BLA submission of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) in 2024Company will present 12-month data from bilateral treated cohorts from the AQUAx AAV-hAQP1 Phase 1 study for treatment of Grade 2/3 radiation-induced xerostomia in the second quarter of 2023Upcoming poster pr

Yahoo | May 11, 2023

MeiraGTx Announces $60 Million Private Placement of Ordinary Shares

LONDON and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has agreed to sell approximately 10.7 million ordinary shares at a price of $5.75 per share. MeiraGTx anticipates aggregate gross proceeds from the private placement will be approximately $60 million. The Company intends to use the proceeds from this private placement to continue to advance its pipeline of innovative gen

Yahoo | May 3, 2023

MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

LONDON and NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced two abstract presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting. The first abstract will present humoral immune response data from the Company’s Phase 1/2 MGT009 trial for the investigational gene therapy botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) in patients with

Yahoo | April 21, 2023

Read More 'MGTX' Stories Here

MGTX Price Returns

1-mo 22.99%
3-mo -14.10%
6-mo 6.30%
1-year -20.05%
3-year -56.28%
5-year N/A
YTD 0.92%
2022 -72.54%
2021 56.80%
2020 -24.38%
2019 107.68%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7117 seconds.